Sir, In drug-naive patients, HIV-1 viral load (VL) is usually measurable, regardless of clinical stage.
1 When this is not the case, the causes must be clarified to ensure appropriate patient care.
We searched the databases of two Parisian hospital laboratories for patients with an unquantifiable VL although they were referred to the hospital for HIV care after a first positive HIV test. Patients were included if they claimed they were unaware of their infection until now, and if the western blot was positive for HIV-1 and negative for HIV-2. No ethics committee approval was required for this retrospective study.
Twenty-seven patients met the criteria over the last 4 years: 89% were originally from Africa. The demographic parameters and test results for these patients are summarized in Table 1 . VL was routinely determined with the Roche Cobas Ampliprep/Cobas TaqMan v2.0 assay (CTAM). A control test was possible for 12 patients and confirmed unquantifiable with the Abbott RealTime assay (ABB) ( Table 1) .
Two patients (nos 22 and 23) who had unquantifiable viraemia with both assays after .6 months of follow-up were considered to be elite controller patients. 2 Their serotyping tests confirmed HIV-1 group M infection, 3 and no antiretroviral drugs (ARV) were detected in their plasma. A woman (patient 21), was suspected to have stopped treatment before the HIV blood test, given the gradual increase in VL to 4.85 log copies/mL over three successive tests in a month. Four other patients (nos 24-27) did not return for subsequent consultations, making their follow-up too short (, 2 months) to determine whether they had recently stopped treatment or had elite controller status.
Finally, ARV intake was detected in the 20 remaining patients (74%): 18 of them had ARV detected in the plasma, and, at the second visit, two others (nos 19 and 20) admitted taking ARV. Some women said they were taking unknown drugs provided by a close friend/relative. The use of a false identity was suspected for three men. One of them (patient 16) retested negative for HIV antibody at a third visit and was believed to have sent an infected and treated person for the previous two blood tests. For the other two (patients 17 and 18), the same drugs were detected in plasma samples and CD4 cell counts were identical. Reverse transcriptase and protease genotyping on proviral DNA showed the sequences from these two patients to be 99.5% identical. By extending our search for similarities (Smartgene System) to the database of the same laboratory, containing data for .4500 patients, we identified four other patients with the same strain, which harboured only one or two nucleotide differences between the samples. These four additional patients were diagnosed with quantifiable viraemia several months before patients 17 and 18. Phylogenetic analysis and bootstrap confirmed the high degree of similarity of the HIV strains harboured by these six patients, 4 whose other biological parameters were also very similar. These patients each consulted only twice, always postponing blood sampling to another day and requesting a medical certificate, after which they were never seen again. These findings suggest that, rather than a transmission cluster, we are dealing here with a single person who returned for all the blood tests over a period of 2 years, with treatment initiation in the meantime. At the second visit, we asked two of these patients to undergo a fingerstick control test, to remove all possible doubt. They categorically refused, before leaving the consultation and never returning.
This study aimed to determine the reasons for which viraemia was sometimes not quantifiable at the time of HIV-1 diagnosis. No HIV-1 quantification discrepancy was observed between CTAM and ABB assays, confirming the efficiency of the V C The Author 2016. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please email: journals.permissions@oup.com CTAM assay v2.0. 5, 6 In these two Parisian hospitals, the presence of ARV in plasma was responsible for viraemia being unquantifiable in most patients (74%). Two situations were observed. In the first, the patient knew he was infected and taking ARV, but he said nothing. The strong taboo concerning HIV in Africans is a real issue and can lead the patient to conceal the actual history of his infection. However, residence permits are facilitated in France for migrants with diseases for which it is difficult to obtain appropriate treatment in the country of origin. Therefore, as related by some patients to our African mediator, ongoing treatment may be concealed during the visit, in order to obtain a residence permit more easily. This may also explain the second situation, in which non-infected individuals sent an infected person (sometimes on treatment) for the blood tests, to obtain a medical certificate. Plasma should therefore be systematically tested for the presence of ARV in this context. Adjustment of the dialogue with patients, to render the discourse more appropriate to the migrant situation, might also help to reduce patient fears, making it easier to obtain correct information about ongoing treatment.
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None to declare. 1-3 Before initiating ART in a person with HIV-1 infection, genotypic antiretroviral (ARV) drug resistance testing should be performed to guide selection of the ARV regimen; if therapy is started before the results of drug resistance testing are available, Department of Health and Human Services guidelines 1 recommend the use of a boosted PI-based regimen (darunavir/ ritonavir) because resistance to PIs emerges slowly and clinically significant transmitted resistance to PIs is uncommon. This choice is due to the finding that transmitted virus may be resistant to at least one ARV drug; data from the USA demonstrate that transmitted virus may be resistant to at least one ARV drug in up to 16% of patients. 4 In Italy, the prevalence of drug resistance mutations has been significantly reduced in recent years (8.2%). 5 We have no data about the efficacy of an integrase inhibitor (InSTI)-containing regimen in PHI; the rapid decrease in HIV-RNA could be associated with HIV-DNA decay with implications for HIV reservoir control. 6 The aim of this study was to assess the efficacy of elvitegravir/cobicistat/ emtricitabine/tenofovir disoproxil fumarate (EVG/C/FTC/TDF) in patients with PHI compared with patients with recent HIV infection (RHI).
We conducted a retrospective study on PHI or RHI patients, followed at the Infectious Diseases Department, San Raffaele Scientific Institute (IDD-HSR), Milan, Italy, who started ART with EVG/C/FTC/TDF. Patients did not sign written consent for the retrospective study; data recorded in the database of the IDD-HSR were used for the analyses. RHI patients included subjects with HIV infection within 1 year since the last negative HIV serological test who started ART within 1 year from HIV diagnosis. Results were expressed as median (IQR) or frequency (%). v 2 or the Wilcoxon rank sum test were used to compare groups. Kaplan-Meier curves were calculated to estimate the time to undetectable viral load (HIV-RNA , 50 copies/mL) and compared by use of the log-rank test. The Cox proportional hazard model was used to estimate factors [including age, baseline CD4!, baseline HIV-RNA, group of patients (PHI versus RHI)] associated with time to undetectable viral load.
Forty-seven patients were enrolled: 23 (49%) PHI and 24 (51%) RHI. Demographic and baseline clinical characteristics are shown in Table 1 . No differences between the two groups were recorded and no major genotypic mutations for InSTIs were found. One patient in the PHI group and one in the RHI group had minor InSTI mutations; one patient in the RHI group had major NRTI mutations.
Over a median follow-up of 64 (47-78) weeks in the PHI group and 37 (23-69) weeks in the RHI group (P " 0.136), time to undetectable viral load was not significantly different between groups; at weeks 4, 12, 24 and 48, the probabilities of undetectable viral load were 5% versus 8%, 35% versus 54%, 85% versus 79% and 100% versus 100% among the PHI and RHI groups, respectively (log-rank test: P " 0.695). Based on multivariate analysis, time to undetectable viral load was delayed in subjects with higher baseline HIV-RNA [adjusted HR (per 0.5 log 10 copies/mL higher) " 0.64, 95% CI 0.47 to 0.88, P " 0.006]; other factors were all not significant.
At week 4 viral decrease was 3.2 (2.5-3.7) log 10 copies/mL in the PHI group and 3.1 (2.9-3.2) log 10 copies/mL in the RHI group (P " 0.622).
At week 48 the CD4! cell count increased in both groups; the CD4! change during follow-up was different between the two groups, with a higher CD4! gain of 350 (207-422) cells/mm 3 in the PHI group versus 251 (181-445) cells/mm 3 in the RHI group, although this was not statistically significant (P " 0.450).
At week 48 the CD4/CD8 ratio increased in both groups without differences between the groups (P " 0.815); we observed a CD4/CD8 gain of 0.35 (0.26-0.68) in the PHI group versus 0.52 (0.21-0.67) in the RHI group. At baseline no patients in the PHI group and two patients in the RHI group had a CD4/CD8 ratio .1; eight (35%) patients in the PHI group and six (25%) patients in the RHI group reached a CD4/CD8 ratio .1 (P " 0.534).
Treatment was well tolerated, without grade 3 or 4 adverse events. No significant difference between the two groups was found for the 48 week trend of bone marrow function, AST, ALT and creatine phosphokinase values, glucose profile (fasting glucose, fasting insulin) and lipid profile (total cholesterol, LDL and HDL cholesterol, triglycerides) (data not shown).
At week 48 renal function was normal in both groups: we observed an estimated glomerular filtration rate (eGFR) of 93 (85-114) mL/min/1.73 m 2 in the PHI group versus 99 (82-101) mL/min/1.73 m 2 in the RHI group (P " 0.829). No patients reached a pathological value of eGFR or had tubulopathy.
Virological efficacy appeared to be similar in PHI and RHI patients treated with EVG/C/FTC/TDF; patients treated during PHI started therapy without waiting for genotypic ART resistance. In patients diagnosed with an acute or recent HIV infection from 2000 to 2010 the overall prevalence of any drug resistance mutation was 14%; NRTI, NNRTI and major PI resistance mutations were detected in 7%, 7% and 3% of patients, respectively, V C The Author 2016. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com
